Triamcinolone-moxifloxacin stabilizes macular thickness after cataract surgery in DR
An intravitreal triamcinolone acetonide-moxifloxacin injection during cataract surgery maintained postoperative central macular thickness stability in patients with preexisting diabetic retinopathy, according to a study.
“Intravitreal triamcinolone-moxifloxacin during cataract surgery is an excellent option to consider when operating on patients with diabetic retinopathy, especially with preexisting macular edema. The treatment stabilizes diabetic macular edema during the postoperative period and eliminates compliance concerns regarding postoperative eye drop use. This is my preferred treatment regimen for this patient population,” study co-author Michael Rauser, MD, told Healio/OSN.
A retrospective chart review included 75 eyes of 64 patients with diabetic retinopathy who underwent cataract surgery. Patients received a single intravitreal injection of Tri-Moxi (triamcinolone acetonide/moxifloxacin, Imprimis Pharmaceuticals) at the conclusion of cataract surgery. Researchers evaluated visual acuity and central macular thickness (CMT) with OCT imaging preoperatively and postoperatively.
Baseline CMT for the cohort was 294 µm, and baseline visual acuity was 0.83 logMAR.
The mean CMT in 46 eyes decreased from 299 µm to 297 µm at 4 to 6 weeks postoperatively. The mean CMT in 34 eyes increased from 317 µm to 344 µm at 6 to 12 weeks postoperatively, with a mean increase of 26 µm (P = .021). From 12 weeks postoperatively or more in 60 eyes, the median CMT increased from 295 µm to 328 µm, a mean increase of 33 µm (P = .0023).
The mean visual acuity at 4 to 6 weeks, 6 to 12 weeks and 12 weeks or more was 0.32 logMAR, 0.35 logMAR and 0.43 logMAR, respectively.